528836-35-3

Upstream product

• 528836-34-2 2-nitro-N,N-bis[2'-(tert-butyldimethylsilyloxy)ethyl]aniline 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 7334-82-9 N,N-bis(2-hydroxyethyl)-2-nitroaniline 

Downstream Products

• 528837-06-1 di-tert-butyl 4-{[2'-(N,N-bis(2''-hydroxyethyl)amino)phenyl]carbamoyloxymethyl}phenoxycarbonyl-L-glutamate 
• 528837-23-2 diallyl 4-{[2'-(N,N-bis(2''-chloroethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528837-04-9 diallyl 4-{[2'-(N,N-bis(2''-hydroxyethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528837-18-5 diallyl 4-{[2'-(N,N-bis(2''-bromoethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528837-24-3 di-tert-butyl 4-{[2'-(N,N-(2''-mesyloxyethyl)(2''-chloroethyl)amino)phenyl]carbamoyloxymethyl}phenyloxycarbonyl-L-glutamate 
• 528837-14-1 diallyl 4-{[2'-(N,N-bis(2''-iodoethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528837-10-7 di-tert-butyl 4-{[2'-(N,N-bis(2''-mesyloxyethyl)amino)phenyl]carbamoyloxymethyl}phenyloxycarbonyl-L-glutamate 
• 528837-09-4 diallyl 4-{[2'-(N,N-bis(2''-mesyloxyethyl)amino)phenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 
• 528837-00-5 di-tert-butyl 4-{[2'-bis(2''-(tert-butyldimethylsilyloxy)ethyl)aminophenyl]carbamoyloxymethyl}phenyloxycarbonyl L-glutamate 
• 528836-98-8 diallyl 4-{[2'-bis(2''-tert-butyldimethylsilyloxyethyl)aminophenyl]carbamoyloxymethyl}phenylcarbamoyl-L-glutamate 

Relevant academic research and scientific papers

ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS

This invention pertains to certain enzyme (CPG2) activated self-immolative nitrogen mustard prodrugs, which are useful in enzyme prodrug therapy (EPT), such as ADEPT and GDEPT, for the treatment of proliferative conditions, such as cancer, and which have

Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT

Nineteen novel potential self-immolative prodrugs and their corresponding drugs have been synthesized for gene-directed enzyme prodrug therapy (GDEPT) with carboxypeptidase G2 (CPG2) as the activating enzyme. The compounds are derived from o- and p-amino